Skip to main content
Midas Edge

Bone Biologics Corp

For the period ended Mar 31, 2025. Filed May 12, 2025.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2025 · Filed May 12, 2025

BBLG$0.34+3.0%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Unaudited Condensed Consolidated Statements of Stockholders’ Equity

Consolidated Statement of Stockholders’ Equity

For the Three Months ended March 31, 2025

(unaudited)

Common Stock · Additional Paid-in · Accumulated · Total Stockholders’
SharesAmountCapitalEquityEquity
Balance at December 31, 20242,953,982$2,953$88,502,082$(85,021,378)$3,483,657
Fair value of vested stock options--50,605-50,605
Options issued to settle accrued bonus--46,183-46,183
Issuance of common shares from ATM, net of costs of $13,029317,060317347,232-347,549
Net Loss---(1,017,092)(1,017,092)
Balance at March 31, 20253,271,042$3,270$88,946,102$(86,038,470)$2,910,902

Consolidated Statement of Stockholders’ Equity

For the Three Months ended March 31, 2024

(unaudited)

Common Stock · Additional Paid-in · Accumulated · Total Stockholders’
SharesAmountCapitalEquityEquity
Balance at December 31, 2023534,238$534$83,814,785$(80,908,958)$2,906,361
Fair value of vested stock options--52,681-52,681
Options issued to settle accrued bonus--77,400-77,400
Proceeds from sale of common stock in public offering, net of offering costs of $490,227344,9383451,503,994-1,504,339
Exercise of pre-funded warrants137,313137--137
Net Loss---(865,970)(865,970)
Balance at March 31, 20241,016,489$1,016$85,448,860$(81,774,928)$3,674,948
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.